Researchers have shown that the presence of the inflammasome mediated by NLRP3 is a marker and drug target for COVID-19-related cytokine storms.
List view / Grid view
Filter the results
COVID-19 is known to infect the lungs; however, the dynamics of viral infection and replication are poorly understood. Alongside the Liverpool School of Tropical Medicine, Professor Lyle Armstrong and colleagues have been working to develop a human lung epithelium model of SARS-CoV-2 infection and replication. In this article, he describes…
Researchers have found that neutralising antibodies for the TNF-alpha and IFN-gamma cytokines can prevent death from SARS-CoV-2 in mice.
An analysis reveals that in comparison to other inflammatory diseases such as cytokine-release syndrome (CRS) and sepsis, the levels of cytokines in severely ill COVID-19 patients is low.
Researchers have found that the cytokines IL-18 and IL-22 can combat and cure rotavirus infections in mice.
Scientists explore whether the anti-stress drug, 4-Phenylbutiric acid (4-PBA), could prevent cytokine storms causing respiratory failure in COVID-19 patients.
Scientists have revealed that the cytokines IL-6 and TNF-α are two biomarkers of inflammation that can predict the severity of COVID-19.
Researchers have found that molecules from ticks called Evasins have the potential to halt cytokine storms, the leading cause of COVID-19 fatalities.
According to a new study, treatments for COVID-19 should focus on cytokines and T-cell counts and their function, rather than patient respiratory function.
Professor Saad Shakir explains why cytokine storms occur in COVID-19 patients and suggests potential therapies for the symptoms of the coronavirus.
Researchers who developed modified proteins say this could be used in the fight against COVID-19, by tackling cytokine storms.
Researchers have created a new kind of immunotherapy using the interleukin-27 (IL-27) cytokine to effectively combat tumours in vitro and in vivo.